Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies.
Mariana PiresAna Cristina RegoPublished in: International journal of molecular sciences (2023)
APOE ε4 allele (ApoE4) is the primary genetic risk factor for sporadic Alzheimer's disease (AD), expressed in 40-65% of all AD patients. ApoE4 has been associated to many pathological processes possibly linked to cognitive impairment, such as amyloid-β (Aβ) and tau pathologies. However, the exact mechanism underlying ApoE4 impact on AD progression is unclear, while no effective therapies are available for this highly debilitating neurodegenerative disorder. This review describes the current knowledge of ApoE4 interaction with mitochondria, causing mitochondrial dysfunction and neurotoxicity, associated with increased mitochondrial Ca 2+ and reactive oxygen species (ROS) levels, and it effects on mitochondrial dynamics, namely fusion and fission, and mitophagy. Moreover, ApoE4 translocates to the nucleus, regulating the expression of genes involved in aging, Aβ production, inflammation and apoptosis, potentially linked to AD pathogenesis. Thus, novel therapeutical targets can be envisaged to counteract the effects induced by ApoE4 in AD brain.
Keyphrases
- cognitive decline
- high fat diet
- oxidative stress
- mild cognitive impairment
- reactive oxygen species
- cognitive impairment
- cell death
- end stage renal disease
- ejection fraction
- chronic kidney disease
- poor prognosis
- dna damage
- insulin resistance
- drug delivery
- long non coding rna
- functional connectivity
- genome wide
- blood brain barrier
- peritoneal dialysis
- cell proliferation
- early onset
- dna methylation
- brain injury
- pi k akt